bevacizumab indications/contra

Stem definitionDrug idCAS RN
humanized origin 4956 216974-75-3

Description:

MoleculeDescription

Synonyms:

  • bevacizumab-awwb
  • mvasi
  • bevacizumab
  • avastin
  • rhuMAb-VEGF
  • bevacituzumab
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 1, 2005 EMA Roche Registration Limited
Feb. 26, 2004 FDA GENENTECH

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 12824.45 38.73 5844 34292 146480 3199243
Disease progression 10928.87 38.73 3454 36682 28805 3316918
Off label use 6167.40 38.73 2599 37537 51378 3294345
Hypertension 4374.63 38.73 1851 38285 36615 3309108
Diarrhoea 4274.25 38.73 2501 37635 101847 3243876
Fatigue 3398.57 38.73 2185 37951 105055 3240668
Proteinuria 3128.59 38.73 856 39280 3850 3341873
Nausea 3070.15 38.73 2206 37930 127439 3218284
Vomiting 2934.78 38.73 1866 38270 87665 3258058
Gastrointestinal perforation 2817.04 38.73 629 39507 876 3344847
Anaemia 2494.32 38.73 1409 38727 52924 3292799
Neutropenia 2448.65 38.73 1186 38950 32200 3313523
Dehydration 2268.97 38.73 1129 39007 32520 3313203
Decreased appetite 2101.38 38.73 1149 38987 40341 3305382
Abdominal pain 2009.42 38.73 1158 38978 45067 3300656
Febrile neutropenia 1833.50 38.73 817 39319 18158 3327565
Neuropathy peripheral 1826.10 38.73 786 39350 16021 3329702
Pyrexia 1778.88 38.73 1323 38813 79792 3265931
Pulmonary embolism 1776.15 38.73 901 39235 26987 3318736
Thrombocytopenia 1729.92 38.73 957 39179 34311 3311412
Epistaxis 1589.63 38.73 682 39454 13769 3331954
Asthenia 1580.74 38.73 1134 39002 64531 3281192
Mucosal inflammation 1567.86 38.73 573 39563 7410 3338313
Neutrophil count decreased 1514.54 38.73 598 39538 9675 3336048
Palmar-plantar erythrodysaesthesia syndrome 1475.11 38.73 520 39616 6012 3339711
Intestinal perforation 1462.47 38.73 429 39707 2579 3343144
Dyspnoea 1461.01 38.73 1303 38833 101631 3244092
Constipation 1341.80 38.73 774 39362 30038 3315685
Endophthalmitis 1334.71 38.73 345 39791 1174 3344549
General physical health deterioration 1308.97 38.73 665 39471 19924 3325799

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01XC07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
FDA EPC N0000193543 Vascular Endothelial Growth Factor Inhibitor
FDA MoA N0000178291 Vascular Endothelial Growth Factor-directed Antibody Interactions
FDA MoA N0000193542 Vascular Endothelial Growth Factor Inhibitors
FDA MoA N0000020007 Vascular Endothelial Growth Factor Receptor Inhibitors
FDA EPC N0000178292 Vascular Endothelial Growth Factor-directed Antibody
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D043924 Angiogenesis Modulating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of colon indication 94260004
Malignant epithelial tumor of ovary indication 254849005
Carcinoma of cervix indication 285432005 DOID:2893
Malignant tumor of fallopian tube indication 363444001 DOID:1964
Malignant tumor of peritoneum indication 363492001
Glioblastoma multiforme indication 393563007
Nonsquamous nonsmall cell neoplasm of lung indication 440173001
Metastatic renal cell carcinoma indication 702392008

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vascular endothelial growth factor A Secreted ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

scroll-->
IDSource
DB00112 DRUGBANK_ID
6771 IUPHAR_LIGAND_ID
D06409 KEGG_DRUG
4021437 VUID
N0000148845 NUI
C0796392 UMLSCUI
253337 RXNORM
409405006 SNOMEDCT_US
409406007 SNOMEDCT_US
4021437 VANDF
18086 MMSL
d05214 MMSL
N0000148845 NDFRT
008586 NDDF
N0000010546 NDFRT
CHEMBL1201583 ChEMBL_ID
D000068258 MESH_DESCRIPTOR_UI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Avastin HUMAN PRESCRIPTION DRUG LABEL 1 50242-060 INJECTION, SOLUTION 100 mg INTRAVENOUS BLA 19 sections
Avastin HUMAN PRESCRIPTION DRUG LABEL 1 50242-061 INJECTION, SOLUTION 400 mg INTRAVENOUS BLA 19 sections